- Investing Ideas
- /
- Hong Kong Biotech Breakthroughs
Hong Kong Biotech Breakthroughs
Results
11
Biotech stocks worldwide which are expected to become profitable in the next 3 years.
11 companies
CARsgen Therapeutics Holdings
Market Cap: HK$12.1b
An investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies, solid tumors, and autoimmune diseases in China.
2171
HK$21.85
7D
-5.4%
1Y
451.8%
Akeso
Market Cap: HK$98.6b
A biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide.
9926
HK$109.80
7D
19.4%
1Y
194.4%
Beijing Luzhu Biotechnology
Market Cap: HK$4.5b
A biotechnology company, focuses on the research and development, production, and sale of human vaccines and therapeutic biologics to prevent and control infectious diseases, and treat cancer and autoimmune diseases in Mainland China.
2480
HK$22.15
7D
-8.3%
1Y
-2.9%
Sichuan Kelun-Biotech Biopharmaceutical
Market Cap: HK$78.4b
A biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, and other therapeutic areas in the People’s Republic of China and internationally.
6990
HK$343.00
7D
4.8%
1Y
136.4%
Everest Medicines
Market Cap: HK$21.8b
A biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets.
1952
HK$67.00
7D
7.7%
1Y
254.5%
CanSino Biologics
Market Cap: HK$12.1b
Develops, manufactures, and commercializes vaccines in the People’s Republic of China.
6185
HK$34.75
7D
0.9%
1Y
86.4%
TYK Medicines
Market Cap: HK$7.4b
A clinical-stage biopharmaceutical company, research, development and commercialization of pharmaceutical products.
2410
HK$20.05
7D
-7.6%
1Y
n/a
Beijing Biostar Pharmaceuticals
Market Cap: HK$1.8b
A synthetic biology-driven biopharmaceutical company, engages in the research and development, production, and commercialization of oncology products in the People’s Republic of China.
2563
HK$8.12
7D
84.1%
1Y
n/a
Cutia Therapeutics
Market Cap: HK$2.8b
An investment holding company, engages in the research, development, manufacture, and commercialization of scalp diseases and care products, and skin care products in the People’s Republic of China and Hong Kong.
2487
HK$8.89
7D
-11.3%
1Y
40.0%
Innovent Biologics
Market Cap: HK$140.8b
A biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People’s Republic of China, the United States, and internationally.
1801
HK$82.35
7D
5.0%
1Y
125.0%
CStone Pharmaceuticals
Market Cap: HK$7.0b
A biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in China and internationally.
2616
HK$5.18
7D
21.3%
1Y
324.6%